Array played with Pfizer’s eagerness to land a deal on time—and got itself a better offer

1st July 2019 Uncategorised 0

When it comes to buying an experienced cancer drug specialist, a bidding war is naturally expected. But in the case of Pfizer’s $11 billion deal for Array BioPharma, that didn’t happen. Still, it didn’t stop the two companies from pressing each other.

More: Array played with Pfizer’s eagerness to land a deal on time—and got itself a better offer
Source: fierce